|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,332.85 INR | +2.91% |
|
+10.00% | -5.59% |
Business description: GlaxoSmithKline Pharmaceuticals Limited
Number of employees: 3,103
Sales by Activity: GlaxoSmithKline Pharmaceuticals Limited
| Fiscal Period: March | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) | 2026 (INR) |
|---|---|---|---|---|---|
Pharmaceuticals | 32.78B | 32.52B | 34.54B | 37.49B | 38.22B |
Geographical breakdown of sales: GlaxoSmithKline Pharmaceuticals Limited
| Fiscal Period: March | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) | 2026 (INR) |
|---|---|---|---|---|---|
India | 31.96B | 31.88B | 33.92B | 36.99B | 37.7B |
Foreign | 819M | 640M | 614M | 505M | 521M |
Executive Committee: GlaxoSmithKline Pharmaceuticals Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Bhushan Akshikar
CEO | Chief Executive Officer | 56 | 2022-11-30 |
Ronojit Biswas
DFI | Director of Finance/CFO | - | 2026-03-31 |
| Chief Tech/Sci/R&D Officer | - | 2024-02-25 | |
Simrat Sohal
CMP | Compliance Officer | - | - |
Shalini Menon
CTO | Chief Tech/Sci/R&D Officer | - | 2024-07-07 |
Composition of the Board of Directors: GlaxoSmithKline Pharmaceuticals Limited
| Director | Title | Age | Since |
|---|---|---|---|
Subesh Williams
BRD | Director/Board Member | 64 | 2017-04-06 |
Renu Sud Karnad
CHM | Chairman | 73 | 2019-03-31 |
| Director/Board Member | 59 | 2020-05-17 | |
Manu Anand
BRD | Director/Board Member | 66 | 2022-05-15 |
Bhushan Akshikar
BRD | Director/Board Member | 56 | 2022-11-30 |
Som Somasundaram
BRD | Director/Board Member | 65 | 2025-03-25 |
Anup Wadhawan
BRD | Director/Board Member | 65 | 2025-03-25 |
Ronojit Biswas
BRD | Director/Board Member | - | 2026-03-31 |
Company details: GlaxoSmithKline Pharmaceuticals Limited
Group companies: GlaxoSmithKline Pharmaceuticals Limited
| Name | Category and Sector |
|---|---|
Biddle Sawyer Ltd. |
Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.91% | +10.00% | -27.22% | +63.15% | 4.19B | |
| -1.21% | -3.04% | +44.03% | +143.07% | 980B | |
| -2.48% | -5.18% | +52.47% | +39.15% | 550B | |
| -2.14% | -4.94% | +16.83% | +57.08% | 382B | |
| +0.25% | -3.09% | +23.33% | +16.04% | 316B | |
| +0.61% | -1.69% | +27.35% | +13.73% | 272B | |
| +0.22% | -3.10% | +24.67% | +30.49% | 268B | |
| +4.59% | +1.98% | -38.43% | -46.26% | 199B | |
| -1.19% | -4.95% | +16.68% | +47.69% | 182B | |
| -1.35% | -1.46% | +14.06% | +59.26% | 154B | |
| Average | +0.02% | -1.71% | +15.38% | +42.34% | 330.65B | |
| Weighted average by Cap. | -0.77% | -3.66% | +29.42% | +63.31% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 500660 Stock
- Company GlaxoSmithKline Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
